Protocol Specific Research

CCSG支持研究护士和临床研究助理，致力于开展和完成 癌症中心项目提出的创新性、可行性或原理验证性临床试验对于 SJCRH对儿科肿瘤学的持续贡献。癌症中心领导层致力于研究方案特定的 这项资源支持研究工作，而且只支持被视为最高优先事项的试验。我们 本补助金第7.0节的汇总表3说明了对基于方案的研究的承诺 应用程序.该表显示，2005年10月1日至2006年9月30日的指数年为373 247例（66%）患者在圣犹达接受治疗性临床试验，作为他们最初治疗的一部分。 在圣犹大的治疗其中85例（85%）为癌症中心方案， 其余15%用于行业或国家协议。此外，在247名参加治疗试验的患者中， 在索引年，56例（23%）同时接受了一项以上的试验， 登记人数。这在很大程度上是由于圣裘德集中精力招募以前接受治疗的病人到圣裘德。 裘德为我们的I/II期开发治疗计划。最后，373名患者在 索引年还促成了549例非治疗性入组， 指数年。

CCSG support of research nurses and clinical research associates dedicated to the conduct and completion of innovative, feasibility or proof-of-principle clinical trials proposed by Cancer Center Programs is critical for SJCRH's continued contribution to pediatric oncology. The Cancer Center leadership is dedicated to protocolspecific research and only trials considered to be of the highest priority are supported by this resource. Our commitment to protocol-based research is illustrated in Summary Table 3 in section 7.0 of this grant application. That table shows that for the index year of October 1, 2005 through September 30, 2006, of 373 patients presenting to St. Jude, 247 (66%) were treated on a therapeutic clinical trial as part of their initial treatment at St. Jude. Eighty-five (85%) of these enrollments were Cancer Center protocols, with the remaining 15% on industry or national protocols. In addition, of the 247 patients enrolling on therapeutic trials during the index year, 56 (23%) were also treated on more than one trial, resulting in 312 therapeutic enrollments. This is largely a result of St. Jude's concentrated effort to recruit previously treated patients to St. Jude for our Phase l/ll Developmental Therapeutics Program. Finally, the 373 patients presenting during the index year also contributed to 549 non-therapeutic enrollments, for a total of 861 protocol enrollments during the index year.